Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30796026 | 1.00 | ALDH1A1 (0.57) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL30794826 | 0.90 | ALDH1A1 (0.61) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL2751773 | 0.90 | ALDH1A1 (0.61) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL30794504 | 0.90 | ALDH1A1 (0.49) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL2750846 | 0.90 | ALDH1A1 (0.49) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL30795889 | 0.84 | RXFP1 (0.52) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL2750933 | 0.84 | RXFP1 (0.52) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL2750992 | 0.83 | ALDH1A1 (0.66) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL30794769 | 0.82 | NPSR1 (0.49) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL2749879 | 0.82 | NPSR1 (0.49) | ALDH1A1HTTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465504-A1 | Novel 2,3-diamino-quinazolinone derivatives and their medical use | NeuroSearch A/S (DK) | 2012-06-20 | — | — | EP | claimed |
| US-8178544-B2 | 2, 3-diamino-quinazolinone derivatives and their medical use | NEUROSEARCH A/S (DK) | 2012-05-15 | — | — | US | claimed |
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEURO SEARCH A/S (DK) | 2010-06-24 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2465504-A1 | Novel 2,3-diamino-quinazolinone derivatives and their medical use | NeuroSearch A/S (DK) | 2012-06-20 | — | — | EP | disclosed |
| US-8178544-B2 | 2, 3-diamino-quinazolinone derivatives and their medical use | NEUROSEARCH A/S (DK) | 2012-05-15 | — | — | US | disclosed |
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEURO SEARCH A/S (DK) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNJ2, KCNN3, KCNK17 | ALDH1A1 1660/4885HTT 893/4885LMNA 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.